This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q3.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 8.89% and 4.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Abbott (ABT) Might Surprise This Earnings Season
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from gradual recovery in Clear Aligner shipment volumes in Q3.
Calix (CALX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Backed by a robust balance sheet, Calix's (CALX) third-quarter earnings are likely to have been driven by technological innovations for upgraded products.
The Zacks Analyst Blog Highlights: Abbott Laboratories, NextEra Energy, Silgan Holdings, UniFirst Corp and Landstar System
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, NextEra Energy, Silgan Holdings, UniFirst Corp and Landstar System
Intuitive Surgical (ISRG) Q3 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect improvement in procedure volume.
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal fourth-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
COVID-19 Antigen Test Launch to Drive Abbott (ABT) Q3 Earnings
by Zacks Equity Research
Abbott (ABT) is expected to register strong sales in the Adult Nutrition category, banking on growing global demand for its nutrition brand Ensure.
An Investment Strategy for Q3 Earnings in a Volatile Market
by Nalak Das
Investment in low-beats stocks with a favorable Zacks Rank and positive Earnings ESP will be a sound strategy to enhance one's portfolio.
Abbott (ABT) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $107.75, marking a -0.57% move from the previous day.
Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus
by Zacks Equity Research
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences' (EW) Q3 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and the INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q3 revenues.
Why Abbott (ABT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Visa, Walmart, Abbott Laboratories, UnitedHealth Group and Oracle
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Walmart, Abbott Laboratories, UnitedHealth Group and Oracle
Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands
by Zacks Equity Research
Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.
Here's Why Momentum Investors Will Love Abbott (ABT)
by Zacks Equity Research
Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Abbott (ABT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott's Data From Interim Clinical Study of ID NOW Positive
by Zacks Equity Research
Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.
Top Research Reports for Visa, Walmart & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Walmart (WMT) and Abbott Laboratories (ABT).
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Coronavirus Drives Testing Stocks: Is There Room for More Upside?
by Urmimala Biswas
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $108.56, moving +1.93% from the previous trading session.